Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities ...

Nasal Polyps Treatment Market Research Report The global nasal polyps treatment market is expected to reach around $4,243.9 million by 2030 ...

Spring officially starts March 20, but we're already in allergy season. Let's talk about the signs, symptoms, treatments, and ...

Chronic rhinosinusitis with nasal polyps presents a substantial clinical burden, affecting nasal airflow, olfactory function, ...

Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...

This study tests a new method to open a patient's nasal passages by a simple mouth guard that uses gentle electrical pulses to regulate the nerves in the nasal cavity, enabling better breathing ...

Herpes simplex virus-1 (HSV-1) is commonly known for causing blisters and sores. But in some cases, the virus can migrate to ...

Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...

The asthma medication reduces congestion in patients with severe, uncontrolled chronic rhinosinusitis with nasal polyps in a ...

My husband has had an awful runny rose for several months. Our GP prescribed Beconase, but that hasn't worked. What advice do you have? Dr Ellie ...

An international collaboration of researchers, sponsored by GSK and working on behalf of the ANCHOR-1 and ANCHOR-2 trial ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review the Biologics License ...